Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Gastroenterology and hepatology indexChapter sections
Purpose and principlesIndications, selection and cautionsMethod and interpretationClinical next stepsRisks, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook9 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

IBD investigations, scoring and treat-to-target monitoring

Gastroenterology and hepatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull

Purpose and principles

Use reproducible clinical scores, biomarkers, endoscopy and cross-sectional imaging to distinguish symptoms from inflammation and make treatment changes against explicit, patient-relevant targets.

The first investigation asks whether chronic inflammatory bowel disease is present and which phenotype it has. At later visits, the question changes: is current treatment controlling inflammation, has structural damage developed, are symptoms coming from another mechanism, and is the medicine safe? Good test selection begins by stating that question. Ileocolonoscopy remains central for diagnosis and colonic mucosa. Cross-sectional enterography maps small-bowel and transmural disease. Pelvic MRI assesses complex perianal tracts. Stool microbiology and C. difficile testing prevent infection being mistaken for relapse. Histology helps confirm chronicity and evaluate dysplasia, but the pathologist needs mapped specimens and clinical context.

Treat-to-target separates three domains. Patient-reported targets include bleeding, stool pattern, pain, fatigue and participation. Intermediate targets include CRP and calprotectin. Longer-term targets include endoscopic control and, for Crohn disease, improvement of transmural complications. Targets should be realistic, recorded and paired with an action deadline. Escalation is inappropriate when objective inflammation is absent and another cause explains symptoms; conversely, complete symptom relief does not justify ignoring persistent ulcers. Monitoring intensity reflects previous severity, location, treatment, postoperative state, cancer risk and the consequences of a missed relapse.

Key points

  • IBD diagnosis is synthetic: symptoms, stool testing, endoscopy, histology and imaging establish chronic inflammation and distribution while excluding infection and alternative pathology.
  • A clinical activity score standardises communication but is not a substitute for judgement; many scores include symptoms that anaemia, infection, bile-acid diarrhoea or irritable bowel physiology can reproduce.
  • Use the same validated score longitudinally for the same question: Truelove and Witts for ASUC, partial Mayo or SCCAI for UC, and Harvey-Bradshaw or another agreed index for Crohn disease.
  • Faecal calprotectin is a non-specific marker of intestinal neutrophilic activity whose trend is most useful when linked to the individual's phenotype, previous values and local assay.
  • CRP is convenient but can remain normal in active disease; albumin, blood count and weight add severity and nutritional context rather than replacing direct bowel assessment.
  • Endoscopy assesses mucosal healing and dysplasia; MR enterography or intestinal ultrasound assesses transmural small-bowel disease, strictures and fistulae; neither modality answers every target.
  • Treat-to-target means agreeing short-term symptom and biomarker goals plus longer-term objective control, then acting when they are missed instead of waiting for irreversible damage.

Indications, selection and cautions

Symptom-inflammatory concordance

Worsening bleeding, stool frequency or pain accompanied by rising calprotectin, CRP or imaging activity makes active inflammation more likely and supports timely restaging.

Symptoms without objective activity

Persistent diarrhoea or pain with repeatedly normal phenotype-appropriate tests should prompt assessment for infection, bile-acid loss, small-intestinal bacterial overgrowth, pelvic-floor or functional disease.

Silent inflammation

An asymptomatic patient may have rising calprotectin, anaemia, growth failure or recurrent endoscopic ulcers and remains at risk of damage despite reporting wellbeing.

Structural progression

Obstructive episodes, prestenotic dilatation, fistulae, abscess or shortened bowel represent cumulative Crohn damage that symptom scores and mucosal inspection may understate.

Drug failure phenotype

Primary non-response, initial response then loss, intolerance and mechanistic failure are different problems; objective inflammation and exposure data help distinguish them.

Dysplasia risk trajectory

Long disease duration, extensive colitis, repeated histological activity, primary sclerosing cholangitis, stricture or prior dysplasia requires a deliberate surveillance pathway separate from flare monitoring.

Red flags requiring action

  • A severity score never overrules shock, peritonism, obstruction, major haemorrhage, toxic dilatation or sepsis; stabilise and image urgently.

Method and interpretation

  1. 01
    Faecal calprotectinFirst step
    Why
    Support diagnosis and track neutrophil-driven luminal inflammation non-invasively.
    Interpretation and limitations
    Use local thresholds and serial trend; infection, NSAIDs, neoplasia and other inflammation can raise it, while isolated proximal or very distal disease may be less well represented.
  2. 02
    CRP, blood count and albumin
    Why
    Assess systemic inflammatory, haematological and nutritional consequences.
    Interpretation and limitations
    A raised CRP or falling albumin can mark burden, but individual CRP response varies and albumin is also influenced by nutrition, loss and dilution.
  3. 03
    Ileocolonoscopy with segmental histology
    Why
    Assess mucosal distribution, healing, chronicity and dysplasia.
    Interpretation and limitations
    Use standardised reporting such as Mayo endoscopic or UCEIS for UC and SES-CD for Crohn where the service supports it; note treatment-created patchiness and procedural completeness.
  4. 04
    MR enterography or intestinal ultrasound
    Why
    Measure small-bowel and transmural activity, stricturing and penetrating complications.
    Interpretation and limitations
    Compare wall thickness, vascularity, oedema and complications with a documented baseline; structural damage may persist after active inflammatory signal falls.
  5. 05

Clinical next steps

01BASELINECreate a reproducible disease mapFirst stepNew IBD is suspected or a transferred patient lacks a clear phenotype and objective baseline.+
  1. 1Record symptoms using an agreed clinical index, but separately document weight, function, steroid exposure, perianal and extra-intestinal disease.
  2. 2Obtain infection tests, calprotectin, CRP, blood count, albumin, renal, liver, iron and phenotype-specific nutrition markers.
  3. 3Use ileocolonoscopy with mapped biopsies plus small-bowel imaging for Crohn suspicion, adding pelvic MRI, upper endoscopy or capsule only when the question requires it.
  4. 4Store extent, behaviour, validated endoscopic activity, histology, complications and patient priorities as the comparator for later treat-to-target review.
02TARGETAgree what response should look likeInduction or a major treatment change is starting and response must be judged fairly.+

Risks, monitoring and follow-up

  • At each review, record the same clinical activity measure plus patient-defined function, steroid burden, adverse events and adherence so change is interpretable.
  • Trend calprotectin using the same local assay where possible and investigate abrupt unexpected change for infection, NSAID exposure or sampling problems.
  • Select endoscopy, enterography, ultrasound or pelvic MRI from known disease location; avoid serial tests that cannot visualise the target pathology.
  • Use a monitoring calendar that separates disease activity, medicine safety, nutrition, bone health, vaccination and dysplasia surveillance responsibilities.
  • After treatment optimisation, close the loop by checking the predefined objective target within an appropriate class-specific interval.
  • Audit missed investigations and unreviewed results because treat-to-target fails when tests are ordered but no clinician owns the response.

Special situations

Scores compress, they do not explain

A number makes severity reproducible but can hide why it is high. Always inspect the component variables and the mechanism generating them.

Choose a test that sees the disease

Calprotectin and colonoscopy may under-represent isolated proximal small-bowel or transmural pathology, while enterography cannot replace targeted dysplasia inspection.

Baseline prevents false change

Without a documented starting endoscopic segment, imaging technique and biomarker response pattern, later apparent improvement or worsening is harder to interpret confidently.

Objective remission is not wellness

Fatigue, pain, anxiety, anaemia and bowel dysfunction can persist after inflammatory healing and deserve active treatment rather than dismissal as no disease.

Drug levels answer narrow questions

Therapeutic drug monitoring can separate underexposure from adequate-exposure failure for selected agents; it cannot diagnose inflammation or replace clinical assessment.

Common pitfalls

  1. 01

    Using one symptom score as proof of mucosal or transmural inflammation without infection testing and objective assessment.

  2. 02

    Applying a calprotectin threshold from another laboratory without considering assay, phenotype and the patient's previous trend.

  3. 03

    Repeating colonoscopy to monitor isolated small-bowel Crohn disease while never imaging the known transmural segment.

  4. 04

    Escalating immunosuppression for functional bowel symptoms after objective inflammatory control.

  5. 05

    Reassuring an asymptomatic patient despite persistent ulcers, rising biomarkers or postoperative recurrence.

  6. 06

    Ordering a biologic drug level without recording dose timing or defining which possible result would change management.

  7. 07

    Mixing Truelove and Witts, Mayo, SCCAI and Harvey-Bradshaw scores as though their categories are interchangeable.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Gastroenterology and hepatologyOriginal SBA

Persistent symptoms in biochemical remission

A patient with treated Crohn disease reports diarrhoea and bloating, but repeated calprotectin, CRP and current phenotype-appropriate imaging show no active inflammation. What is the best next approach?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Gastroenterology and hepatology topics →
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • BSG Inflammatory bowel disease guideline 2025Current activity assessment, treatment targets and drug-monitoring guidance.
  • NICE HTG320 Faecal calprotectin recommendationsNational diagnostic use and limitations of faecal calprotectin.
  • NICE NG129 Crohn disease recommendationsAssessment and monitoring of Crohn disease and postoperative recurrence.
  • NICE NG130 Ulcerative colitis recommendationsActivity-based UC treatment and surveillance context.
  • IBD UK Standards 2026 ongoing carePersonalised plans, access and closed-loop monitoring standards.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
Therapeutic drug monitoring can explain non-response to selected biologics, but levels and antibodies must be interpreted with timing, inflammation, adherence and the clinical decision.
Rapid clinical deterioration with a previously low calprotectin may reflect perforation, abscess, thrombosis or non-inflammatory illness and needs direct assessment.
  • Capsule endoscopy is unsafe when a stricture or obstruction has not been excluded.
  • Do not delay treatment of acute severe colitis while awaiting an elective full colonoscopy or a send-away drug level.
  • Unexpected high-grade dysplasia, invisible dysplasia or a stricture needs expert pathology, endoscopy and colorectal MDT review rather than routine surveillance recall.
    • Pelvic MRI
    Why
    Map perianal fistula anatomy, abscesses and relationship to sphincters.
    Interpretation and limitations
    Anatomical closure and inflammatory activity may lag behind symptom improvement; interpret with examination under anaesthesia and luminal rectal activity.
  • 06
    Therapeutic drug and antidrug antibody assay
    Why
    Clarify selected loss of response and guide pharmacokinetic versus mechanistic change.
    Interpretation and limitations
    A low concentration without antibodies, low level with neutralising antibodies and adequate exposure with active disease imply different actions; assay, timing and drug class matter.
  • 07
    Stool pathogen testing
    Why
    Exclude an infectious trigger before major immunosuppression escalation.
    Interpretation and limitations
    Choose the panel from presentation and exposure, always considering C. difficile in significant colitis; detection can represent disease requiring treatment alongside an IBD flare.
    • 1
    Set an early patient-reported goal such as resolution of bleeding or improved stool frequency and function, acknowledging symptoms from non-inflammatory mechanisms.
  • 2Choose an intermediate objective marker, usually a calprotectin or CRP trend appropriate to previous responsiveness, with a date for reassessment.
  • 3Define the longer-term anatomical target, such as mucosal control on endoscopy or transmural improvement on imaging, and when the test will be proportionate.
  • 4Write the action if each target is missed: verify adherence and infection, optimise exposure, switch mechanism, assess structure or discuss surgery.
    • 03DISCORDANCEResolve symptoms and tests that disagreeClinical score, biomarkers, endoscopy or imaging point in different directions.+
    1. 1Confirm test quality, timing, bowel preparation, stool collection, medication exposure and whether the modality actually sees the known disease location.
    2. 2If symptoms persist without objective inflammation, assess infection, anaemia, bile-acid diarrhoea, bacterial overgrowth, stricture, pelvic-floor and functional contributors.
    3. 3If objective inflammation persists without symptoms, discuss cumulative damage and cancer risk and optimise treatment rather than relying on perceived remission alone.
    4. 4Use multidisciplinary radiology, pathology and endoscopy review for continuing discordance before exposing the patient to another high-risk medicine or operation.
    04LOSS OF RESPONSEDistinguish pharmacokinetic from mechanistic failurePreviously effective advanced therapy no longer controls objectively confirmed inflammation.+
    1. 1Exclude infection, non-adherence, missed administration, structural complication and a symptom-only mimic before labelling drug failure.
    2. 2Use class-appropriate trough concentration and antibody testing when evidence and local access support a decision, documenting the sampling point.
    3. 3Optimise dose or interval for low exposure without prohibitive antibodies, consider within-class change for immunogenic failure, and change mechanism when adequate exposure fails.
    4. 4Reconfirm objective response after intervention and involve surgery when ongoing damage is localised or medical options are unlikely to reverse the anatomy.